Supplementary Materials and Methods

Materials
AlexaFluor 488 NHS Ester (Succinimidyl Ester) (A20000) was purchased from Thermo Fisher Scientific and dimethyl sulfoxide (10080110) were purchased from Fisher Scientific (UK). Rabbit anti-mouse CD81 (bs-6934R) and CD9 (bs-2489R) antibodies were purchased from Insight Biotechnology (UK). HRP-linked goat antirabbit (7074S) was purchased from Cell Signalling Technology (USA). Collagenase Type IV (LS004188) and DNase I (LS002007) were purchased from Worthington. Rat anti-mouse CD45-APC (103111; isotype -400611), F4/80-FITC (123107; isotype -400505), CD11b-PE (101207; isotype -400607), CD47-APC (127513; isotype -400511) antibodies, and 10X RBC lysis buffer (420301) were purchased from BioLegend (UK). 70 µm cell strainers (352350) were purchased from VWR (UK).
Cell culture
B16F10 and GL261 cells were both cultured in Advanced RPMI medium supplemented with 10% exosome-depleted FBS, 1% GlutaMax, and 1% PenicillinStreptomycin in an incubator maintained at 37C and 5% CO2.
Fluorescent labelling of exosomes
AlexaFluor 488 NHS Ester (Alexa-NHS) was used to fluorescently label lysine (Lys) residues on the surface of B16F10 exosomes (ExoB16). Alexa-NHS was reacted with ExoB16 at a 1:400 molar ratio (Lys:Alexa-NHS -it was assumed that 1 exosome is equivalent to 1 BSA molecule i.e. containing 59 lysine residues) protected from light for 1 hour at room temperature (RT). Labelled ExoB16 (Alexa-ExoB16) was purified from excess unreacted Alexa-NHS using Sepharose® CL-2B columns (self-packed according to the dimensions of the commercially available NAP-5™ columns) optimised such that exosomes elute in the first 2 x 500 µl fractions.
Exosomal surface proteins detection by dot blot following mock radiolabelling
ExoB16 were subjected to a mock membrane-radiolabelling protocol (as described in the Methods section of the main manuscript, but without the addition of 111 InCl3 to the 0.2 M ammonium acetate buffer pH 5.5). 40 µl of 5 x 10 10 p/ml unlabelled and labelled ExoB16 in PBS was spotted onto a nitrocellulose membrane (10 µl at a time) and dried under a nitrogen stream. Non-specific binding on the membrane was blocked by 3% milk in Tris-buffered saline with 0.1% Tween-20 (TBS-T, pH 7.6) at RT for 1 hour. The membrane was incubated with primary antibodies (1:1000 dilution) in 3% milk in TBS-T (i.e. the blocking buffer) at 4°C overnight. Washing was done 3 times with TBS-T for 5 minutes each. The membrane was then incubated with HRP-conjugated rabbit antimouse secondary antibody (1:1000 dilution) in the blocking buffer for 1 hour at RT.
Washing was done 3 times with TBS-T for 5 minutes each as above. The washed membrane was incubated with the ECL substrate for 3 min, and then imaged using the Gel Doc™ system (Bio-Rad, US) under the "Intense Bands" setting. The acquired imaged was processed using Image Lab™ software (Bio-Rad, US). . The tumours were excised, and each tumour was chopped into fine pieces in 1 ml serum-free media, which was then topped up to 4 ml with serum-free media. The following enzymes were added to the tumour suspension at their respective final concentrations: Collagenase Type IV (2 mg/ml) and DNase I
In vitro
(150 µg/ml). The tumours were digested for 45 minutes at 37°C in a shaking water bath (320 rpm), vortexing every 15 minutes. The reaction was stopped by adding 10 ml 1% BSA solution (prepared in PBS), and the cell suspension was passed through a 70 µm cell strainer. Tumour-derived cells in the filtrate were washed once with PBS and subjected to a red blood cell lysis step by adding 5 ml 1X RBC lysis buffer to the cell pellet post-washing and incubated for 5 minutes at RT. The reaction was stopped by adding 25 ml PBS. Cells were pelleted (500 g, 5 Biochemical analysis of B16F10 exosomes. Histograms illustrate the detection of CD81 and CD9 using flow cytometry on exosomes isolated from B16F10 cells. Exosomes were coupled to aldehyde/sulphate latex beads prior to detection. Exo-beads complex were subsequently stained using a 2-step labelling (anti-CD81 or anti-CD9 1° ab/Cy5-conjugated 2° ab). Exo-beads complex stained with Cy5-conjugated 2° ab only was used as control. The shift in FL4 signals from the control indicates positive expression of the markers on the exosomes.
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Fig. S2
Exosome and protein elution profile by gel filtration. B16F10 exosomes and BSA solution were loaded separately onto Sepharose® CL-2B columns self-packed according to the dimensions of the commercially available NAP-5 columns. 3.5 x 10 11 exosomes (100 µl) were loaded onto the column. (A) 80 µg/ml and (B) 800 µg/ml BSA solution was loaded onto the column (100 µl for both concentrations). Eight 500 µl fractions were collected and the particle number and protein concentration in each fraction was measured using Nanosight and microBCA assay respectively. Values are expressed as mean ± SD, where n=3. InCl3 to the 0.2 M ammonium acetate buffer). Equal numbers (40 µl from 5 x 10 10 p/ml stock) of both unlabelled and labelled of ExoB16 were then blotted on a nitrocellulose membrane, followed by blocking in 3% milk solution. The membrane is then incubated with primary rabbit anti-mouse CD9 and CD63 antibodies, followed by incubation with HRP-linked goat anti-rabbit secondary antibodies. After addition of the ECL substrate, the membrane was imaged using Gel Doc™ system (Bio-Rad, USA) and the image processed using Image Lab™ software (Bio-Rad, USA). Histograms illustrate the detection of CD47 on exosomes isolated from B16F10 (ExoB16 -murine melanoma), IENS (ExoIENS -murine glioblastoma stem cells), HEK293 (ExoHEK -human epithelial) and Panc1 (ExoPanc1 -human pancreatic adenocarcinoma) cell lines using flow cytometry. Exosomes were coupled to aldehyde/sulphate latex beads prior to detection. Exo-beads complex were then stained with APC-conjugated anti-CD47 or their respective isotype controls (rat anti-mouse for murine exosomes, or mouse anti-human for human exosomes). The shift in FL4 signals indicates positive expression of CD47 on the exosomes.
Fig. S11
Comparison of tumour-associated macrophages (TAMs) population between tumours developed in immunocompetent and immunodeficient mice. (A) Representative gating strategy used to identify TAM population among cells isolated from tumours developed in both C57Bl/6 and NSG mice. Cells were triple-stained with APCconjugated anti-CD45, FITC-conjugated anti-F4/80 and PE conjugated anti-CD11b antibodies. TAMs are identified as CD45+ F4/80+ CD11b+. First, viable cells which are CD45+ are selected, followed by cells which are both F4/80+ CD11b+. (B) Population of TAM isolated from tumours developed in C57Bl/6 and NSG mice, expressed as the percentage of CD45+ F4/80+ CD11b+ cells in total cells isolated from the tumours. Values are expressed as mean ± SD, where n=3, and Student's t-test was used for statistical analysis (p* < 0.05).
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